Pharmaceutical Contract Manufacturing Market

The global pharmaceutical contract manufacturing market is projected to reach USD 319.6 billion by 2029 from USD 200.9 billion in 2024, at a CAGR of 9.7% during the forecast period of 2024 to 2029. The growing adoption of pharmaceutical corporations outsourcing drug development and production, driven by the rising costs of in-house development and the expanding demand for generic treatments as well as the nearing expiration of patents for popular drugs, the growing acceptance of pharmaceutical companies outsourcing drug development and manufacturing. Some legal limitations regarding contract manufacturing in the pharmaceutical sector are projected to impede the sector.

The global LNP raw materials & services market is fragmented, with Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi Apptec (China), WuXi Biologics (China), Merck KGaA (Germany), Siegfried Holding AG (Switzerland), Evonik Industries AG (Germany), Boehringer Ingelheim International (Germany), FUJIFILM Holding Corporation (Japan), Piramal Pharma Solutions (India), Samsung Biologics (South Korea) accounting for the 15-20% of the market share globally.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US) dominates the pharmaceutical contract manufacturing market, with the largest market share in 2023. The company provides a wide range of services, including formulation development, process development, analytical services, and commercial manufacturing services. The market is substantial in size. Its wide range of services and strong regional and brand awareness help to explain its big market share. The corporation keeps its dominance by concentrating on organic development plans including service introductions. For example, in March 2024, the company introduced a wide range of cold and ultra-cold services allowing worldwide clinical trial innovation and biorepository storage options.

Catalent, Inc. (US) is a well-established CDMO that delivers development solutions for medicines, biologics, consumer & animal health products together with sophisticated delivery methods. To satisfy the needs of the pharmaceutical and biotechnology sectors, the company presents several oral, injectable, and respiratory delivery systems. Catalent offers unique, patented technology, products, and services. Its industrial plants, development hubs, and sales offices spread around the globe reflect To stay on top of things, the organization emphasizes teamwork.

The Lonza Group (Switzerland) offers integrated solutions to the pharmaceutical, biotech, consumer health, and specialty chemical businesses. The Lonza Group (Switzerland) acts as a COMO, the company offers complete pharma value chain integrated solutions spanning molecule to patient using different technologies. Its ultimate users include government research organizations, biotechnology firms, pharmaceutical businesses, consumer and healthcare product makers, formulators, and service providers. Lonza concentrated on geographic development for 2023 expansion.

Related Reports:

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule, Oral Liquid), Biologics (API, FDF), Packaging & Labelling, Fill-finish), End Users - Global Forecasts to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]